213 citations,
June 2017 in “Rheumatology” The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.
182 citations,
November 2017 in “Molecular Aspects of Medicine” The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
157 citations,
May 2021 in “Endocrine Reviews” Early diagnosis and individualized treatment improve outcomes for Congenital Adrenal Hyperplasia.
60 citations,
September 2013 in “Alimentary Pharmacology & Therapeutics” Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
54 citations,
December 2007 in “Best Practice & Research Clinical Endocrinology & Metabolism” Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.
41 citations,
October 2012 in “Australian and New Zealand Journal of Psychiatry” Negative expectations can cause adverse effects in patients even without active treatment, and managing this nocebo effect involves better communication and patient-clinician relationships.
25 citations,
January 2022 in “Endocrine journal” Long COVID patients may have hormonal imbalances linked to their symptoms.
5 citations,
January 2016 in “Journal of The American Academy of Dermatology” Skin doctors should know about skin and kidney disease links to prevent serious kidney problems.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
6 citations,
December 2023 in “Lancet. Infectious diseases/The Lancet. Infectious diseases” SIM01 significantly reduced post-COVID symptoms and is safe.
45 citations,
April 2019 in “International Immunology” The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
25 citations,
February 2022 in “JAAD International” Some COVID-19 patients lose hair, with the most common type linked to male hormones and possibly increasing the risk of severe illness.
6 citations,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
1 citations,
February 2023 in “Animals” 5 citations,
September 2011 in “Bioorganic & Medicinal Chemistry Letters” Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
17 citations,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
11 citations,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.
7 citations,
April 2009 in “Bioorganic & Medicinal Chemistry Letters” Diphenyl ethers can potentially reduce excess oil production when applied on the skin, helping treat conditions like acne.
65 citations,
November 2004 in “Journal of the American Academy of Dermatology” Bimatoprost can cause excessive eyelash growth.
23 citations,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
November 2008 in “Journal of Generic Medicines” The document updates on EU legal changes, including pharmaceutical patents, class actions in Italy, and various drug-related rulings.
7 citations,
April 2017 in “Health Economics, Policy and Law” The document suggests reevaluating the patent system to ensure public benefits from pharmaceutical privileges and to encourage more significant innovations.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
21 citations,
July 2018 in “The Journal of Sexual Medicine” The 2018 update to the ED care model added a new severity score and stressed a detailed evaluation of both physical and psychological aspects.
33 citations,
June 2007 in “International Journal of Pharmaceutics” The conclusion is that measuring how drugs partition into artificial sebum is important for predicting their delivery into hair and sebaceous follicles, and it provides better information than traditional methods.
21 citations,
June 2017 in “Journal of The American Academy of Dermatology” Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.
15 citations,
August 2008 in “Toxicology Letters” High doses of minoxidil can harm marmoset hearts and kidneys, possibly affecting humans similarly.
11 citations,
March 2009 in “Bioorganic & Medicinal Chemistry Letters” Chemicals called 4-(alkylthio)- and 4-(arylthio)-benzonitrile derivatives can potentially reduce oil production on skin, which could help treat conditions like acne and hair loss.
6 citations,
July 2005 in “Farmaco” A quick and simple method was created to identify minoxidil in hair-growth products using micellar electrokinetic capillary chromatography.
March 2009 in “Journal of The American Academy of Dermatology” AGA patients have higher rates of metabolic syndrome and carotid atheromatosis, suggesting early screening and prevention is important.